Is Johnson & Johnson's $1 Billion Cell Therapy Investment a Game Changer

Related Articles

Why is Johnson & Johnson Selling its Orthopedics Unit

7 months ago

Johnson & Johnson's "New Era" of Growth: Why the Market Underestimates Its Innovative Pipeline

3 months ago

What's Driving Johnson Controls' Recent Momentum Ahead of Q2 Earnings

6 months ago

What Makes Tethis' SmartBioSurface® a Game-Changer in Cell Analysis

4 months ago

Category

You may also like

News•1 months ago

Health Care's Next Act: Tailwinds Emerging Across R&D Cycle

Pharmaceuticals are rebounding as U.S. drug pricing clarity emerges, shifting focus to patent expirations and innovation-driven differentiation. Companies like JNJ and AZN, with diversified portfolios...

Share

Stock News•2 months ago

Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines

Johnson & Johnson agreed to pay $785 million upfront for an exclusive option to acquire Sail Biomedicines for $2.58 billion, expanding its pipeline in programmable medicines.

JNJ

Share

Stock News•3 months ago

Kyverna Therapeutics: The Autoimmune CAR T Beachhead Is Bigger Than SPS

Kyverna Therapeutics is positioned to pioneer autoimmune CAR T with miv-cel, targeting FDA approval by late 2026 after regulatory alignment for a rolling BLA submission in SPS. The company holds $236M...

CAR

Share